BioInvent is a research-based pharmaceutical company developing innovative antibody drugs targeting cancers with unmet clinical need.
Our drug development programmes are supported by our human antibody development platform. This consists of a proprietary antibody library, n-CoDeR®, and in-house technology for the rapid selection, screening and identification of antibodies with excellent affinity and selectivity for targets.
BioInvent has a high level of competence in antibody drug discovery, preclinical and clinical development. The Company also has many years' experience in process development and antibody manufacturing, which we carry out at our own facilities. Alongside our in house and partnered drug-development programmes we offer antibody discovery and development services to customers.
BioInvent's business model and technology platform have been validated through numerous partnerships. These include a co-development agreement with Bayer, Daiichi Sankyo, Mitsubishi Tanabe, Servier and others.
BioInvent employs around 50 people and is based in Lund, Sweden. The Company listed on the NASDAQ OMX Stockholm in 2001.